Orbital Therapeutics is a Cambridge, MA RNA-medicines company that launched in April 2023 with a $270M Series A — one of the largest ever — led by ARCH Venture Partners with a16z Bio + Health and Newpath Partners. Co-founded and led by CEO Giuseppe Ciaramella (former Moderna/Beam executive), Orbital is building a first-in-kind platform integrating established and emerging RNA modalities (mRNA, circular, self-amplifying) with next-generation delivery.
Biotech📍 Cambridge, MAFounded 2023
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is Orbital Therapeutics going public?
No. Orbital Therapeutics is private and has not filed to go public. There is no S-1 on file.
What is Orbital Therapeutics' valuation in 2026?
No confirmed valuation is on record for Orbital Therapeutics. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Orbital Therapeutics filed an S-1?
No public S-1 is on file for Orbital Therapeutics.
Who are Orbital Therapeutics' investors?
Orbital Therapeutics' investors include ARCH Venture Partners, a16z Bio + Health, Newpath Partners.
How much has Orbital Therapeutics raised?
Orbital Therapeutics has raised $270M in total across 1 disclosed round, most recently a Series A of $270M in Apr 2023.
Is Orbital Therapeutics publicly traded — can you buy Orbital Therapeutics stock?
No. Orbital Therapeutics is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Orbital Therapeutics on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Giuseppe Ciaramella
Founded
2023
HQ
Cambridge, MA
Total Raised
$270M
Growth
Well-funded platform stage after $270M Series A
Last Round
Series A — $270M (Apr 2023) · Lead: ARCH Venture Partners
IPO Status
private
Fundraising Status
Series A · $270M · 3y 5mo ago
privateTotal raised $270M1 disclosed rounds
Funding History
Round
Amount
Date
Lead Investor
Post-Money
Series A
$270M
Apr 2023
ARCH Venture Partners
—
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Orbital Therapeutics — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-27. Re-checked weekly.
Talent Signal
Hiring trend
▶ Hiring steady
0% vs 2026-08
Open roles
18
via careers page
Product-build share
67%
engineering, research, product, design
Trajectory
steady
heavy product build — 67% of open roles are product-building functions (engineering/research/product) — 7 of 18 open roles are medical.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Research & developmentClinical trials & researchIndependent researchMedical information onlineMedical resourcesSearch U.S. Medical Information
Counted from Orbital Therapeutics's live job board as of 2026-09-14; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Founders & Key People
Giuseppe Ciaramella
Investors
ARCH Venture Partners · a16z Bio + Health · Newpath Partners
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.